PDL BioPharma Inc. (PDLI)

2.46
NASDAQ : Health Technology
Prev Close 2.53
Day Low/High 2.44 / 2.54
52 Wk Low/High 2.25 / 3.89
Avg Volume 1.12M
Exchange NASDAQ
Shares Outstanding 114.20M
Market Cap 288.93M
EPS -0.50
P/E Ratio 8.72
Div & Yield N.A. (N.A)
PDL BioPharma Stock To Go Ex-dividend Tomorrow (PDLI)

PDL BioPharma Stock To Go Ex-dividend Tomorrow (PDLI)

The ex-dividend date for PDL BioPharma (Nasdaq:PDLI) is tomorrow, December 6, 2011. Owners of shares as of market close today will be eligible for a dividend of 15 cents per share. At a price of $6.36 as of 9:30 a.m., the dividend yield is 9.5%.

PDL BioPharma Inc. Stock Upgraded (PDLI)

PDL BioPharma Inc. Stock Upgraded (PDLI)

PDL BioPharma (Nasdaq:PDLI) has been upgraded by TheStreet Ratings from a sell to hold.

Hedge Fund 13F Stock Picks: Profiting From Idea Season

Hedge Fund 13F Stock Picks: Profiting From Idea Season

Hedge fund manager third quarter stock picks are revealed, and sorting through the 13F filings provides value investing ideas.

Making the Most of Idea Season

The 13HF filings currently pouring into the SEC offer good clues about stocks that are worth further investigation.

PDL BioPharma's CEO Discusses Q3 2011 Results - Earnings Call Transcript

PDL BioPharma's CEO Discusses Q3 2011 Results - Earnings Call Transcript

PDL BioPharma's CEO Discusses Q3 2011 Results - Earnings Call Transcript

Fascinating Ideas for Under $10

The Value Line low-priced high-value portfolio has proffered several stocks worth consideration for long-term investors.

PDL BioPharma Stock To Go Ex-dividend Tuesday (PDLI)

PDL BioPharma Stock To Go Ex-dividend Tuesday (PDLI)

The ex-dividend date for PDL BioPharma (Nasdaq:PDLI) is Tuesday, September 6, 2011. Owners of shares as of market close today will be eligible for a dividend of 15 cents per share. At a price of $5.84 as of 10 a.m., the dividend yield is 9.8%.

Borrow From the Best

Sifting through the activities of super investors can lead to interesting investment ideas.

PDL BioPharma Inc. Stock Downgraded (PDLI)

PDL BioPharma Inc. Stock Downgraded (PDLI)

PDL BioPharma (Nasdaq:PDLI) has been downgraded by TheStreet Ratings from from a buy to sell.

PDL Biopharma's CEO Discusses Q2 2011 Results - Earnings Call Transcript

PDL Biopharma's CEO Discusses Q2 2011 Results - Earnings Call Transcript

PDL Biopharma's CEO Discusses Q2 2011 Results - Earnings Call Transcript

3 Magic Formula Investing Stock Lists

3 Magic Formula Investing Stock Lists

Here are lists of top Magic Formula stocks with best dividend yields, best price-to-sales ratios and best price-to-book ratios.

PDL BioPharma Stock To Go Ex-dividend Monday (PDLI)

PDL BioPharma Stock To Go Ex-dividend Monday (PDLI)

The ex-dividend date for PDL BioPharma (Nasdaq:PDLI) is Monday, June 6, 2011. Owners of shares as of market close today will be eligible for a dividend of 15 cents per share. At a price of $6.35 as of 9:32 a.m., the dividend yield is 9.2%.

2 New Stock Picks From Baupost's Klarman

2 New Stock Picks From Baupost's Klarman

Klarman picked up a gold and networking stock in the first quarter.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade significantly higher from current levels.

PDL BioPharma Inc. Stock Upgraded (PDLI)

PDL BioPharma Inc. Stock Upgraded (PDLI)

PDL BioPharma (Nasdaq:PDLI) has been upgraded by TheStreet Ratings from a hold to buy.

PDL Biopharma's CEO Discusses Q1 2011 Results - Earnings Call Transcript

PDL Biopharma's CEO Discusses Q1 2011 Results - Earnings Call Transcript

PDL Biopharma's CEO Discusses Q1 2011 Results - Earnings Call Transcript

PDL BioPharma Inc. Stock Upgraded (PDLI)

PDL BioPharma Inc. Stock Upgraded (PDLI)

PDL BioPharma (Nasdaq:PDLI) has been upgraded by TheStreet Ratings from a sell to hold.

PDL BioPharma CEO Discusses Q4 2010 Results - Earnings Call Transcript

PDL BioPharma CEO Discusses Q4 2010 Results - Earnings Call Transcript

PDL BioPharma CEO Discusses Q4 2010 Results - Earnings Call Transcript

PDL Biopharma, Medicis: Small-Cap Winners

PDL Biopharma, Medicis: Small-Cap Winners

TheStreet presents a rundown of small-cap stocks making notable moves higher.

PDL BioPharma Stock Hits New 52-Week Low (PDLI)

PDL BioPharma Stock Hits New 52-Week Low (PDLI)

PDL BioPharma (Nasdaq:PDLI) hit a new 52-week low Tuesday as it changed hands at $4.74 compared with its previous 52-week low of $4.81. PDL BioPharma is currently trading at $4.74 with 2.5 million shares changing hands as of 1:17 p.m. as compared to the average daily trading volume of 2.4 million.

Hercules Offshore: Small-Cap Winner

Hercules Offshore: Small-Cap Winner

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

Wendy's/Arby's, BioLase: Small-Cap Winners

Wendy's/Arby's, BioLase: Small-Cap Winners

TheStreet presents a rundown of Thursday's winners in the small-cap space

Be Wary of Stocks That Grow Via Goodwill

Be Wary of Stocks That Grow Via Goodwill

Overpaying for acquisitions doesn't create value; it removes capital that could have been returned in the form of dividends or buybacks.

PDL BioPharma CEO Discusses Q3 2010 Results – Earnings Call Transcript

PDL BioPharma CEO Discusses Q3 2010 Results – Earnings Call Transcript

PDL BioPharma CEO Discusses Q3 2010 Results â¿¿ Earnings Call Transcript

6 Stocks That Could Double in the Next Year

Here's a look at six stocks that could deliver 100% returns in the next 12 months.

PDL BioPharma, Inc. Q2 2010 Earnings Call Transcript

PDL BioPharma, Inc. Q2 2010 Earnings Call Transcript

PDL BioPharma, Inc. Q2 2010 Earnings Call Transcript

PDL BioPharma Forecasts 3Q Revenue Below Estimates

PDL BioPharma Forecasts 3Q Revenue Below Estimates

PDL BioPharma say it expects $71M in third quarter revenue; analysts called for $77.5M

Movers Roundup: Headwaters, Keryx Biopharma

Movers roundup: Headwaters drops, Keryx Biopharma gains on kidney treatment trial results

PDL BioPharma Rises On Better-than-seen Outlook

PDL BioPharma Rises On Better-than-seen Outlook

PDL BioPharma shares rise on better-than-expected revenue outlook for royalties

Google, Amgen, Tyson Foods Are Big Movers

Google, Amgen, Tyson Foods, KB Home, Johnson Controls are among big market movers Friday

TheStreet Quant Rating: C- (Hold)